Raymond James Financial Services Advisors’s DiaMedica Therapeutics DMAC Stock Holding History

Raymond James Financial Services Advisors’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$48.3K	Buy	+11,520	New	+$42.5K	﹤0.01%	3363

Other funds holding DMAC

CLG

Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James Financial Services Advisors's DMAC Position: Q3 2024 in Review

Raymond James Financial Services Advisors opened a new position in DiaMedica Therapeutics (DMAC) in Q3 2024: 11,520 shares worth $48.3K. The stake represents ﹤0.01% of the portfolio and ranks #3363 among its holdings.

40 funds tracked by Wall St. Rank hold DMAC as of Q3 2024.

Raymond James Financial Services Advisors held 11,520 shares of DiaMedica Therapeutics worth $48.3K as of Q3 2024.
DiaMedica Therapeutics was a new Raymond James Financial Services Advisors position in Q3 2024.
DiaMedica Therapeutics made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #3363 holding.
40 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.